Biovica International AB (publ) Total Liabilities
Biovica International AB (publ) total liabilities. Based on the latest financial reports, Biovica International AB (publ) (BIOVIC-B) has total liabilities worth Skr31.14 Million SEK (≈ $3.35 Million USD) as of July 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BIOVIC-B asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biovica International AB (publ) (2014–2025)
Total liabilities of Biovica International AB (publ) from 2014 to 2025. This chart illustrates how Biovica International AB (publ)'s total liabilities have evolved over time, based on quarterly financial data.
Biovica International AB (publ) Competitors by Total Liabilities
The table below lists competitors of Biovica International AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Invert Graphite Limited
AU:IVG
|
Australia | AU$287.84K |
|
Agrimin Ltd
AU:AMN
|
Australia | AU$11.41 Million |
|
elumeo SE
XETRA:ELB
|
Germany | €15.03 Million |
|
VR Resources Ltd
V:VRR
|
Canada | CA$233.89K |
|
Priceworth International Bhd
KLSE:7123
|
Malaysia | RM149.37 Million |
|
Global Engine Group Holding Limited Ordinary Shares
NASDAQ:GLE
|
USA | $7.78 Million |
|
Western Mines Group Ltd
AU:WMG
|
Australia | AU$251.75K |
|
Narmada Agrobase Limited
NSE:NARMADA
|
India | Rs-593.37 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Biovica International AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Biovica International AB (publ).
Liquidity & Leverage Metrics
Biovica International AB (publ) Total Liabilities Ratios Explained
Biovica International AB (publ) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.56 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biovica International AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biovica International AB (publ) (2014–2025)
The table below shows the annual total liabilities of Biovica International AB (publ) from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | Skr21.74 Million ≈ $2.34 Million |
-37.46% |
| 2024-04-30 | Skr34.77 Million ≈ $3.74 Million |
+3.32% |
| 2023-04-30 | Skr33.65 Million ≈ $3.62 Million |
+22.18% |
| 2022-04-30 | Skr27.54 Million ≈ $2.96 Million |
+175.73% |
| 2021-04-30 | Skr9.99 Million ≈ $1.07 Million |
-17.05% |
| 2020-04-30 | Skr12.04 Million ≈ $1.30 Million |
+37.43% |
| 2019-04-30 | Skr8.76 Million ≈ $942.93K |
+24.14% |
| 2018-04-30 | Skr7.06 Million ≈ $759.55K |
+25.19% |
| 2017-04-30 | Skr5.64 Million ≈ $606.74K |
+73.26% |
| 2016-04-30 | Skr3.25 Million ≈ $350.18K |
-65.54% |
| 2015-04-30 | Skr9.44 Million ≈ $1.02 Million |
+134.67% |
| 2014-04-30 | Skr4.02 Million ≈ $433.09K |
-- |
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more